Myfreesia (Ethinylestradiol, Levonorgestrel)

• Myfreesia, a combined oral contraceptive, acts on the hormonal regulation of the menstrual cycle to prevent pregnancy.
• Contraception: prevents unintended pregnancy in women of reproductive age.
• Menstrual cycle regulation: helps achieve more predictable bleeding patterns.
• Acne management: may improve hormonal acne associated with menstrual fluctuations.

• Myfreesia provides both estrogen (ethinylestradiol) and progestogen (levonorgestrel) which suppress the hypothalamic‑pituitary‑ovarian axis, inhibiting the mid‑cycle surge of luteinizing hormone and follicle‑stimulating hormone, thereby preventing ovulation. The progestogen also thickens cervical mucus, reducing sperm penetration, while the estrogen stabilises the endometrial lining.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: tension‑type or migraine‑like pain.
• Breast tenderness: temporary swelling or discomfort.
• Spotting or breakthrough bleeding: irregular light bleeding.
• Weight gain: modest fluid retention.
• Mood changes: irritability or mild depression.

Serious or Rare Side Effects

• Thromboembolic events: deep‑vein thrombosis or pulmonary embolism.
• Stroke or transient ischemic attack.
• Myocardial infarction: heart attack risk, especially in smokers over 35.
• Severe hypertension: sudden rise in blood pressure.
• Liver tumor: benign hepatic adenoma.
• Allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Myfreesia, clinicians should assess individual risk factors and counsel patients on proper use.

• Cardiovascular risk assessment: evaluate history of clotting disorders, hypertension, or smoking.
• Liver function review: avoid use in severe hepatic impairment.
• Smoking status: contraindicated in women over 35 who smoke.
• Drug interaction check: review concurrent medications that may reduce efficacy.
• Missed pill guidance: provide clear instructions for managing skipped doses.
• Store at below 25°C: keep in the original pack, protect from moisture.

Myfreesia can interact with several medicines that alter hormone metabolism or affect clotting risk.

Major Interactions (Avoid)

• Rifampin: induces hepatic enzymes, reducing contraceptive effectiveness.
• Phenytoin: enzyme inducer that may lower hormone levels.
• Efavirenz: antiretroviral that decreases plasma concentrations.
• St. John’s wort: herbal inducer leading to reduced efficacy.
• Ketoconazole: potent CYP3A4 inhibitor, may increase hormone exposure.

Moderate Interactions (Monitor Closely)

• SSRIs (e.g., fluoxetine): may increase bleeding tendency.
• Diuretics: can affect electrolyte balance and blood pressure.
• Antihypertensives (e.g., ACE inhibitors): monitor blood pressure changes.
• Digoxin: possible alteration in serum levels.
• Fluconazole: moderate CYP3A4 inhibition, may raise hormone levels.